zenocutuzumab
merus
['meru', 'zenocutuzumab']
#asco22: merus wants to tackle a rare genomic fusion in oncology that impacts about 5,000 new patients in the us each year, and the biotech thinks its interim efficacy data can lead zenocutuzumab to become the first approved med for those patients. 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs